TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32697766

Group type: EXPERIMENTAL
Intervention: DNA methylation at sites cg14866069, cg23666362, cg20045320, cg07839457, cg07677157, cg09615688
Number of subjects: 12300

Group type: EXPERIMENTAL
Intervention: DNA methylation at sites cg17086398, cg12619262, cg18424841
Number of subjects: 12300

Group type: EXPERIMENTAL
Intervention: DNA methylation at each site
Number of subjects: 12300

Group type: EXPERIMENTAL
Intervention: cg20045320, cg07839457, cg07677157
Number of subjects: 12300

Group type: EXPERIMENTAL
Intervention: cg20045320, cg07839457
Number of subjects: 12300

Group type: EXPERIMENTAL
Intervention: cg20045320, cg07839457, cg17086398
Number of subjects: 12300
Study: 35902662

Group type: EXPERIMENTAL
Intervention: Anodal-tDCS (10 min duration, 1.5 mA intensity, targeting Fp3 location)
Number of subjects: 96

Group type: COMPARATOR
Intervention: tDCS-sham (control group)
Number of subjects: 96
Study: 33336223

Group type: EXPERIMENTAL
Intervention: Lower quartile of plasma Aβ42/40 (≤0.103)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Lower quartile of plasma Aβ42/40 (≤0.103) among APOE ε4 non-carriers
Number of subjects: 477

Group type: COMPARATOR
Intervention: Upper quartile of plasma Aβ42/40 (>0.123)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Plasma Aβ42/40
Number of subjects: 477
Study: 32796301

Group type: EXPERIMENTAL
Intervention: Biosilicate conical implants
Number of subjects: 45

Group type: COMPARATOR
Intervention: Polymethylmethacrylate (control)
Number of subjects: 45
Study: 35998278

Group type: EXPERIMENTAL
Intervention: Sutureless aortic valve replacement (SuAVR)
Number of subjects: 66
Study: 34610939

Group type: EXPERIMENTAL
Intervention: POC urine tenofovir testing and viral load monitoring
Number of subjects: 540

Group type: COMPARATOR
Intervention: Standard-of-care (laboratory-based VL testing at months 6 and 12)
Number of subjects: 540
Study: 32890770

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation exercise program (HREPro)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 121
Study: 34117756

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine plus darunavir/ritonavir
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine plus raltegravir
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 234
Study: 36288885

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) full dose (400 mg TID)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) reduced dose (200 mg TID)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 40
Study: 33725978

Group type: EXPERIMENTAL
Intervention: Critical Thinking Intervention (CTI)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 103
Study: 35605475

Group type: EXPERIMENTAL
Intervention: 75 g of glucose
Number of subjects: 72

Group type: COMPARATOR
Intervention: Stevia-sweetened water (placebo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acute stress
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Glucose consumption
Number of subjects: 72
Study: 32748261

Group type: EXPERIMENTAL
Intervention: Aerobic endurance training on bicycle ergometers, 3 times per week for 40-50 min/session for 26 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Balance and tone training, 3 times per week for 40-50 min/session for 26 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 180
Study: 35383544

Group type: EXPERIMENTAL
Intervention: VRET + attention guidance training (AGT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard VRET
Number of subjects: 21
Study: 32671449

Group type: EXPERIMENTAL
Intervention: Tumescent infiltration of lidocaine and epinephrine 20 minutes prior to incision.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Wise-pattern, inferior pedicle breast reduction (Control group).
Number of subjects: 40
Study: 32871585

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Chemotherapy-only
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: HSCT in CR1 for patients with favorable ELN 2017 risk
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: HSCT in CR1 for patients with negative NPM1 minimal residual disease (MRD)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: HSCT in CR1 for patients with KB score >=40
Number of subjects: 656
Study: 33840177

Group type: EXPERIMENTAL
Intervention: Intertruncal (IT) approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Corner pocket (CP) approach
Number of subjects: 60
Study: 33769425

Group type: EXPERIMENTAL
Intervention: Viewing distance at AL/2 (35 cm)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Viewing distance at AL (70 cm)
Number of subjects: 65
Study: 34038297

Group type: EXPERIMENTAL
Intervention: S-contact glass
Number of subjects: 30

Group type: COMPARATOR
Intervention: M-contact glass
Number of subjects: 30
Study: 36332503

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective peripheral nerve block (PNB)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sub-dissociative dose ketamine (SDK)
Number of subjects: 111
Study: 33256540

Group type: EXPERIMENTAL
Intervention: Expressed self-contempt during brief psychiatric treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-contempt measure associated with weaker alliance rated by patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-contempt measure associated with stronger alliance rated by therapists
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High self-contempt expression
Number of subjects: 50
Study: 34339653

Group type: EXPERIMENTAL
Intervention: Adjuvant oxaliplatin with S‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant oxaliplatin with capecitabine
Number of subjects: 0
Study: 34811623

Group type: EXPERIMENTAL
Intervention: Normalized-uncertainty intervention (what was currently unknown but that scientific uncertainty is expected)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Ambiguity condition (emphasized what was currently unknown)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control condition (what was currently known)
Number of subjects: 449
Study: 32048083

Group type: EXPERIMENTAL
Intervention: Tofacitinib continuous treatment (10 mg twice daily)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Tofacitinib interrupted treatment (withdrawn for 2 weeks, then reinitiated)
Number of subjects: 198
Study: 36409665

Group type: EXPERIMENTAL
Intervention: Postdischarge Developmental Support Program (PDSP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 44
Study: 33411952

Group type: EXPERIMENTAL
Intervention: Exercise combined with ischaemic compression technique (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Exercise alone (Group 2)
Number of subjects: 50
Study: 32049271

Group type: EXPERIMENTAL
Intervention: Elder-Friendly Approaches to the Surgical Environment (EASE) model
Number of subjects: 684
Study: 35248048

Group type: EXPERIMENTAL
Intervention: Equia™ group with H‐GIC (Equia Forte™)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CHX‐Equia™ group with H‐GIC (Equia Forte™)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketac™ group with H‐GIC (Ketac Universal™)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CHX‐Ketac™ group with H‐GIC (Ketac Universal™)
Number of subjects: 40
Study: 33071088

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate 50 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 80
Study: 35240317

Group type: EXPERIMENTAL
Intervention: NO3‐ supplementation (140 ml of concentrated NO3‐ beetroot juice, 9.7 mmol, 0.6 gm NO3‐)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NO3‐ supplementation
Number of subjects: 13

Group type: COMPARATOR
Intervention: NO3‐ depleted beetroot juice (placebo)
Number of subjects: 13
Study: 32026846

Group type: EXPERIMENTAL
Intervention: Multicomponent rehabilitation programme including an exercise programme delivered at home.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional task practice, strategies to improve adherence, provision of appropriate aids and equipment.
Number of subjects: 0
Study: 36440523

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aloevera mouthwash
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no mouthwash)
Number of subjects: 90
Study: 34242442

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Exercise combined with dietary modification
Number of subjects: 50000
Study: 32353436

Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 554
Study: 34366317

Group type: EXPERIMENTAL
Intervention: Maximal isometric contraction position for short right LLD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maximal isometric contraction position for short left LLD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Resting position for short right LLD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Resting position for short left LLD
Number of subjects: 100
Study: 33449120

Group type: EXPERIMENTAL
Intervention: Breathewell (DCT intervention)
Number of subjects: 14978

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 14978
Study: 32655753

Group type: EXPERIMENTAL
Intervention: Counseling professional ethics principles (six counseling sessions)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Training manual (control group)
Number of subjects: 84
Study: 34999850

Group type: EXPERIMENTAL
Intervention: Higher average physical activity (PA) over 4 years
Number of subjects: 68132

Group type: COMPARATOR
Intervention: Became active (PA baseline <9 MET-h/week to PA year 3 ≥9 MET-h/week)
Number of subjects: 68132

Group type: COMPARATOR
Intervention: Remained active (PA baseline and PA year 3 ≥9 MET-h/week)
Number of subjects: 68132

Group type: COMPARATOR
Intervention: Decreased activity (PA baseline ≥9 MET-h/week to PA year 3 <9 MET-h/week)
Number of subjects: 68132
Study: 34077643

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg intravenously every 2 weeks for up to 1 year)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 35213469

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic decision support accessed by anesthesia providers before or during surgery.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intraoperative medications prescribed based on pharmacogenomic results.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Total medications prescribed considering pharmacogenomic results.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Genomically high-risk medications administered.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Genomically cautionary medications administered.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Provider surveys on pharmacogenomic result accessibility.
Number of subjects: 71
Study: 33022324

Group type: EXPERIMENTAL
Intervention: Fit & Strong! Plus (F&S! Plus)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Fit & Strong! (F&S!)
Number of subjects: 413
Study: 36164414

Group type: EXPERIMENTAL
Intervention: CyclAGel 0.05%
Number of subjects: 627

Group type: COMPARATOR
Intervention: Vehicle eye drops
Number of subjects: 627
Study: 32928503

Group type: EXPERIMENTAL
Intervention: Self-management program for joint protection and physical activity with nursing support (n = 112)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard care for rheumatology (n = 112)
Number of subjects: 224
Study: 35831218

Group type: EXPERIMENTAL
Intervention: Team Clinic
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 86
Study: 33235055

Group type: EXPERIMENTAL
Intervention: Gammar nail
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail Antirotation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intertrochanteric Antegrade Nail
Number of subjects: 120
Study: 35739043

Group type: EXPERIMENTAL
Intervention: Delivering peer support
Number of subjects: 58
Study: 32449083

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 32745706

Group type: EXPERIMENTAL
Intervention: Heel fat pad thickness measurement using ultrasonography
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Heel fat pad thickness measurement in males
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Heel fat pad thickness measurement in females
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Correlation of heel fat pad thickness with height and body mass in males
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Correlation of heel fat pad thickness with age in males
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Correlation of heel fat pad thickness with height and body mass in females
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Correlation of heel fat pad thickness with age in females
Number of subjects: 1126
Study: 34935999

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral erector spinae plane block (ESPB)
Number of subjects: 50
Study: 32125536

Group type: EXPERIMENTAL
Intervention: Balafilcon A lens
Number of subjects: 37

Group type: COMPARATOR
Intervention: Samfilcon A lens
Number of subjects: 37
Study: 35850058

Group type: EXPERIMENTAL
Intervention: Dance intervention (six sessions of hospital-based dance instruction and 16 weeks of home-based practice)
Number of subjects: 176

Group type: COMPARATOR
Intervention: General health consultation (control group)
Number of subjects: 176
Study: 35544244

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP vaccine
Number of subjects: 2199
Study: 33487188

Group type: EXPERIMENTAL
Intervention: Voucher scheme membership
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Non-recipients (Control)
Number of subjects: 1944

Group type: EXPERIMENTAL
Intervention: Voucher scheme membership (for lowest socioeconomic group)
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Non-recipients (Control) in lowest socioeconomic group
Number of subjects: 1944
Study: 32502088

Group type: EXPERIMENTAL
Intervention: Numbered jerseys
Number of subjects: 48

Group type: COMPARATOR
Intervention: Work attire (Control)
Number of subjects: 48
Study: 32898930

Group type: EXPERIMENTAL
Intervention: Contralateral Villalta score (cl-VS)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Contralateral Villalta score (cl-VS) > 4
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Postthrombotic syndrome (PTS)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Correlation between baseline cl-VS and ipsilateral Villalta score (VS)
Number of subjects: 680
Study: 36884054

Group type: EXPERIMENTAL
Intervention: Subcutaneous nitroglycerin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 33081531

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 3730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study: 35546633

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 34274016

Group type: EXPERIMENTAL
Intervention: Psychosocial Navigator (PSN) intervention with monthly screening results and tailored recommendations for psychosocial distress and mental health symptoms.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 0
Study: 36355991

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT-A) treatment (10U-25U for temporalis muscle and 30U-75U for masseter muscle)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT-A) treatment
Number of subjects: 14
Study: 35935300

Group type: EXPERIMENTAL
Intervention: Continuous wave 4 Hz
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Continuous wave 20 Hz
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Extended wave 4/20 Hz
Number of subjects: 108
Study: 35260824

Group type: EXPERIMENTAL
Intervention: Care notebook plus peer support for 12 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Care notebook (control)
Number of subjects: 300
Study: 35972592

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting risk of catheter-related thrombosis (CRT) based on logistic regression analysis
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting risk of CRT
Number of subjects: 647
Study: 33891929

Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cystectomy with extracorporeal urinary diversion (eRARC)
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cystectomy with intracorporeal urinary diversion (iRARC)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: pT-stage
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: pN-stage
Number of subjects: 916
Study: 33165612

Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (15.8 mg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (5.2 mg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (2.4 mg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (1.3 mg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPECTRUM investigational cigarettes (0.4 mg/g)
Number of subjects: 0
Study: 33055441

Group type: EXPERIMENTAL
Intervention: Oral intake of ceramide-containing food (0.8 mg of dihydroceramide) for 12 weeks
Number of subjects: 0
Study: 33517534

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Prior CEVD
Number of subjects: 253

Group type: COMPARATOR
Intervention: Both PCI and CABG
Number of subjects: 253
Study: 34674222

Group type: COMPARATOR
Intervention: Palbociclib 125 mg once daily (q.d.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg q.d. plus erythromycin 500 mg three times daily for seven days
Number of subjects: 11
Study: 35428210

Group type: EXPERIMENTAL
Intervention: Hypofractionated treatment arm (20 × 3 Gy)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Conventional fractionated treatment arm (35 × 2 Gy)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 538
Study: 33078479

Group type: EXPERIMENTAL
Intervention: Aspirin (placebo-controlled trial)
Number of subjects: 19114
Study: 36104548

Group type: EXPERIMENTAL
Intervention: Additional preoperative teleconsent consultation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard informed consent on the day of surgery (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 34443987

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention for prenatal anxiety
Number of subjects: 27
Study: 32516245

Group type: EXPERIMENTAL
Intervention: EORTC criteria
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PERCIST
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: mRECIST
Number of subjects: 75
Study: 35436329

Group type: EXPERIMENTAL
Intervention: Power training (3 days per week for 12 months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Low-intensity sham exercise control (3 days per week for 12 months)
Number of subjects: 103
Study: 34172436

Group type: EXPERIMENTAL
Intervention: efpeglenatide 6 mg weekly (QW)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: efpeglenatide 16 mg monthly (QM)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: efpeglenatide 6 mg QW and 16 mg QM
Number of subjects: 47

Group type: COMPARATOR
Intervention: liraglutide 1.8 mg daily (QD)
Number of subjects: 47
Study: 35226547

Group type: EXPERIMENTAL
Intervention: Intravenous Alteplase before Endovascular Thrombectomy
Number of subjects: 640
Study: 33107645

Group type: EXPERIMENTAL
Intervention: Intervention group (ABC model training)
Number of subjects: 130
Study: 33375474

Group type: EXPERIMENTAL
Intervention: UAV-based RGB imagery methodology for yield estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yield estimation using UAV-based RGB imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial distribution analysis of fruit densities and weights
Number of subjects: 0
Study: 34054617

Group type: EXPERIMENTAL
Intervention: PSYCHOnlineTHERAPYfix (8 in-person sessions + 8 online self-help sessions)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: PSYCHOnlineTHERAPYflex (0 to 16 online self-help sessions)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard Cognitive Behavioral Therapy (CBT)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: All interventions (PSYCHOnlineTHERAPYfix, PSYCHOnlineTHERAPYflex, and CBT)
Number of subjects: 900
Study: 32040956

Group type: EXPERIMENTAL
Intervention: Honey (8 times per day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no honey)
Number of subjects: 74
Study: 33726568

Group type: EXPERIMENTAL
Intervention: eCoFit physical activity intervention (20-week duration, including group sessions and smartphone app)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study: 34992358

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT) at 3 L/min via nasal cannula
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (ambient air) at 3 L/min via nasal cannula
Number of subjects: 32
Study: 32473338

Group type: EXPERIMENTAL
Intervention: Chimney EVAR (CHEVAR) using Endurant stent-graft
Number of subjects: 165